Multiple Treatments for Tuberculosis in the Central Area of a Metropolis, 2008-2016: Profiles, Causes and Characteristics
PDF (Português (Brasil))

Keywords

.

How to Cite

1.
Guinsburg Hamburger F, Penon Rujula MJ. Multiple Treatments for Tuberculosis in the Central Area of a Metropolis, 2008-2016: Profiles, Causes and Characteristics. Bepa [Internet]. 2022 Jun. 9 [cited 2024 Nov. 24];16(188). Available from: https://periodicos.saude.sp.gov.br/BEPA182/article/view/37654

Abstract

Introduction: Tuberculosis still afflicts millions worldwide, with a
considerable number of cases in Brazil, mainly in the central region of the city
of São Paulo. A significant proportion of patients needs more than a single
course of treatment, demanding a better understanding about the causes and
consequences of these retreatments. Objective: To study the demographic,
epidemiological and clinical characteristics of patients with more than one
treatment for tuberculosis notified between 2008 and 2016, in the Central Region
of São Paulo Municipality. Methods: Cross-sectional epidemiological study
with secondary data obtained from TBWeb system of São Paulo State Health
Department. Inclusion criteria: those reported and treated as a tuberculosis case
in the central region of São Paulo City at least twice between 2008 and 2016.
Demographic, epidemiological and clinical data were analyzed with SPSS
21.0. Results: Among 4105 patients with tuberculosis in the central region of
São Paulo, occurred 570 retreatments in 249 patients. Of 249 patients 72.3%
were male, mean age 37.2±14 years old, being 113 HIV+. The most common
reasons for retreatment were: abandonment of previous treatment (59.4%),
relapse (28.1%), and treatment failure (10%). Forty-five patients (37.5% of
those tested) presented some degree of drug resistance. The outcomes of 249
patients were: cure (46.5%), abandonment (26.5%), and death (12%). HIV+
status and previous abandonment were associated with the worse outcomes.
Retreatment due to the previous treatment failure was associated with cure.
Conclusion: Multiples profiles occur in patients with many treatments in the
studied area. They are the heterogeneous group, with different needs to be met
by the health system.

https://doi.org/10.57148/bepa.2019.v.16.37654
PDF (Português (Brasil))

References

Dheda K, Barry CE, Maartens G.

Tuberculosis. Lancet. 2016; 387:1211-26.

Ministério da Saúde (BR). Secretaria

de Vigilância em Saúde. Brasil Livre

da Tuberculose: evolução dos cenários

epidemiológicos e operacionais da doença.

Boletim Epidemiológico. 2019; 50:9

Martinez VN. Equidade em saúde: o caso

da tuberculose na comunidade de bolivianos

na cidade de São Paulo [dissertação].

São Paulo: Faculdade de Saúde Pública

da Universidade de São Paulo; 2010.

Reis DC, Almeida TA, Quites HF,

Sampaio MM. Epidemiological profile

of tuberculosis in the city of Belo

Horizonte (MG), from 2002 to 2008.

Rev. bras. epidemiol. 2013;16:592-602.

Ministério da Saúde (BR). Manual

de Recomendações para o Controle

da Tuberculose no Brasil [internet].

Brasília: Ministério da Saúde; 2011

[acesso em 19 abr 2017]. Disponível

em: http://bvsms.saude.gov.br/bvs/

publicacoes/manual_recomendacoes_

controle_tuberculose_brasil.pdf

Ministério da Saúde (BR). Secretaria

de Vigilância em Saúde. Indicadores

prioritários para o monitoramento do Plano

Nacional pelo Fim da Tuberculose como

Problema de Saúde Pública no Brasil.

Boletim Epidemiológico. 2017; 48:8.

Centers for Disease Control and Prevention

(CDC). Plan to combat extensively drugresistant tuberculosis: recommendations

of the Federal Tuberculosis Task Force.

MMWR recomm. rep. 2009; 58(RR-3):1-43.

Fiske CT, Yan F, Hirsch-Moverman Y et al.

Risk factors for treatment default in close

contacts with latent tuberculosis infection.

Int. j. tuberc. lung. dis. 2014;18(4):421-7.

O’Donnell MR, Daftary A, Frick M

et al. Re-inventing adherence: toward

a patient-centered model of care for

drug-resistant tuberculosis and HIV. Int.

j. tuberc. lung. dis. 2016;20(4):430-4.

Trajman A, Long R, Zylberberg D,

Dion MJ, Al-Otaibi B, Menzies D.

Factors associated with treatment

adherence in a randomised trial of latent

tuberculosis infection treatment. Int. j.

tuberc. lung. dis. 2010; 14(5):551-9.

Rubinowicz A, Bartlett G,

MacGibbon B, Greenaway C,

Ronald L, Munoz M, et al. Evaluating

the role of primary care physicians in

the treatment of latent tuberculosis:

a population study. Int. j. tuberc.

lung. dis. 2014; 18(12):1449-54.

Dheda K, Gumbo T, Maartens G et

al. The epidemiology, pathogenesis,

transmission, diagnosis, and management

of multidrug-resistant, extensively

drug-resistant, and incurable tuberculosis.

Lancet Respir Med. 2017; 5:291-360.

Ragonnet R, Trauer JM, Denholm

JT, Marais BJ, McBryde ES. High

rates of multidrug-resistant and

rifampicin-resistant tuberculosis among

re-treatment cases: where do they come

from? BMC infect. dis. 2017;17:36.

Theron G, Jenkins HE, Cobelens F,

Abubakar I, Khan AJ, Cohen T, et

al. Data for action: collection and

use of local data to end tuberculosis.

Lancet. 2015; 386:2324-33.

Wejse C, Patsche CB, Kuhle A, Bamba

FJV, Mendes MS, Lemvik G et al. Impact

of HIV-1, HIV-2, and HIV-1+2 dual

infection on the outcome of tuberculosis.

Int. j. infect. dis. 2015; 32: 128-34

Nliwasa M, MacPherson P, Gupta‐Wright

A, Mwapasa M, Horton K, Odland JØ,

et al. High HIV and active tuberculosis

prevalence and increased mortality

risk in adults with symptoms of TB: a

systematic review and meta‐analyses.

J. int. aids soc. 2018; 21(7):e25162.

Ministério da Saúde (BR). Secretaria de

Vigilância em Saúde. Implantação do Plano

Nacional pelo Fim da Tuberculose como

Problema de Saúde Pública no Brasil:

primeiros passos rumo ao alcance das metas.

Boletim Epidemiológico. 2018; 49:11

Cardoso MA, do Brasil PEAA, Schmaltz

CAS, Sant’anna Fm, Rolla VC. Tuberculosis

Treatment Outcomes and Factors

Associated with Each of Them in a Cohort

Followed Up between 2010 and 2014.

Biomed Res Int. 2017;2017:3974651.

Hirsch-Moverman Y, Daftary A, Franks

J, Colson PW. Adherence to treatment for

latent tuberculosis infection: systematic

review of studies in the US and Canada. Int.

j. tuberc. lung. dis. 2008; 12(11):1235-54.

Muller AM, Osorio CS, Silva DR, Sbruzzi

G, Dalcin PTR. Interventions to improve

adherence to tuberculosis treatment:

systematic review and meta-analysis. Int.

j. tuberc. lung. dis. 2018; 22(7):731-40.

Menzies D, Adjobimey M, Ruslami R et al.

Four Months of Rifampin or Nine Months

of Isoniazid for Latent Tuberculosis in

Adults. N. Engl. j. med. 2018; 379:440-53.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2022 Flávio Guinsburg Hamburger, Maria Josefa Penon Rujula

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...